Skip to content
Wenlo
Sign in
← Markets

Whitehawk Therapeutics, Inc.

David James Lennon (CHIEF EXECUTIVE OFFICER) reports WHWK insider transactions

4WHWKFiled Sep 15, 2026, 3:07 PM ET· Period Sep 15, 2026

About this filing

Whitehawk Therapeutics, Inc. (WHWK) filed Form 4 (insider transaction) with the SEC on Sep 15, 2026. Form 4 reports a company insider’s trades in the company’s shares.

Key facts

Insider
David James Lennon · CHIEF EXECUTIVE OFFICER, Director
DateTransactionSharesPriceValueHeld afterOwnership
Sep 15, 2026A · grantStock option (right to buy)Footnotes F1+193,957$0.00$0.00193,957Direct
Sep 15, 2026A · grantRestricted Stock UnitsFootnotes F2, F3+193,957$0.00$0.00193,957Direct
Footnotes
  1. F1 Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date and 1/48th of the total shares subject to the option shall vest every month thereafter such that all shares subject to the option shall be fully vested on the four-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean September 15, 2026.
  2. F2 Each restricted stock unit ("RSU") represents a contingent right to receive one share of Whitehawk Therapeutics, Inc. Common Stock.
  3. F3 Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date, and twenty five percent (25%) of the shares subject to the award shall vest on each of the next three Vesting Commencement Date anniversaries thereafter. "Vesting Commencement Date" shall mean September 15, 2026.

More WHWK filings

Not investment advice. Summaries can contain errors; the SEC filing is the official record.